Records containing: Multiple Myeloma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2022-06-14Revlimid 5 mg Capsules Special Use-results Surveillance (All-case Surveillance)
-
CLINICAL_TRIALS study record update · 2022-06-14Revlimid 5 mg Capsules Special Use-results Surveillance of Long Term Use
-
CLINICAL_TRIALS study record update · 2022-05-31Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment Including Subjects Undergoing Hemodialysis: A Phase 2, Open-label, Multicenter Trial
-
CLINICAL_TRIALS study record update · 2022-05-27Empliciti (Elotuzumab) Postmarketing Surveillance in Korean Patients With Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2022-05-25A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Using a Conditioning Regimen of Fludarabine, Melphalan, and Bortezomib
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2022-05-23IFM 2014-02 Study: A Randomized Phase III Study of Bortezomib-Melphalan 200 Conditioning Regimen Versus Melphalan 200 for Frontline Transplant Eligible Patients With Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2022-05-20Efficacy and Safety Evaluation of BCMA-UCART（Allogeneic Engineered T-cells Expressing Anti-BCMA Chimeric Antigen Receptor）in the Treatment of Relapsed or Refractory Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2022-05-19Evaluation of Whole Body Examination by MRI Integrating the "Zero Time Eco" Sequence (ZTE, Pseudo-CT) for the Detection of Bone Lesions in Multiple Myeloma: Comparison With Pet / CT and Whole Body Scanner
-
CLINICAL_TRIALS study record update · 2022-05-17Safety and Efficacy Evaluation of Autologous BCMA-CART for Treating Relapsed or Refractory Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2022-05-11A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With RRMM Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor.
-
CLINICAL_TRIALS study record update · 2022-05-06A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 (Acalabrutinib) and Pembrolizumab in Subjects With Hematologic Malignancies
-
CLINICAL_TRIALS study record update · 2022-05-06A Phase II Clinical Trial of Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance
-
CLINICAL_TRIALS study record update · 2022-05-06Comparison of 68Ga-pentixather and 68Ga-pentixafor PET/CT in Patients With Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2022-05-06A Phase II Study to Investigate Biological Correlates of Clinical Response to Panobinostat in Haematological Malignancy
-
CLINICAL_TRIALS study record update · 2022-05-05A Phase I, Open Label Dose Escalation Trial of Orally Administered N-methyl-pyrrolidone (NMP) in Patients With Relapsed or Refractory Myeloma
-
CLINICAL_TRIALS study record update · 2022-05-03An Open-Label, Non-Comparative, Two-Cohort, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Pomalidomide and Dexamethasone (IPd, Cohort A) or With Lenalidomide and Dexamethasone (IRd, Cohort B) in Patients With Relapsed/Refractory Multiple Myeloma Previously Receiving a Parenteral Proteasome Inhibitor-based Treatment Regimen (US MM-7)
-
CLINICAL_TRIALS study record update · 2022-05-03Phase 1/2 Investigator Sponsored Study of Selinexor in Combination With High-Dose Melphalan Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2022-04-28Evaluating Study of Clinical Treatment of Multiple Myeloma Based on Analytical Omics
-
CLINICAL_TRIALS study record update · 2022-04-26LCI-HEM-DRMM-DPEM-001: Phase II Study of Daratumumab-Pembrolizumab for Multiple Myeloma Patients With ≥ Three Prior Lines of Therapy
-
CLINICAL_TRIALS study record update · 2022-04-26A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2022-04-25A Prospective Cohort Study of Patients With Plasma Cell Disorders (PCDs) in PKUFH
-
CLINICAL_TRIALS study record update · 2022-04-21LCI-HEM-MYE-PurD-001: Phase II Study of Daratumumab Pre-Mobilization and Post-Autologous Stem Cell Transplant in Patients With Multiple Myeloma and Sub-Optimal Response to Induction
-
CLINICAL_TRIALS study record update · 2022-04-15Analysis of Genomic Alterations in Sporadic Cases of Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2022-04-14A Randomized Parallel Phase 2 Study of Elotuzumab Plus Lenalidomide (Elo/Rev) for the Treatment of Serologic Relapse/Progression While on Lenalidomide Maintenance for Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2022-04-13An Open-Label, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of BMCA and GPRC5D Dual Target CAR-T Cells Therapy in Patients With Relapsed or Refractory Multiple Myeloma